Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

G Andersen; N H Jensen; Lona Louring Christrup; S H Hansen; P Sjøgren

Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

G Andersen, N H Jensen, Lona Louring Christrup, S H Hansen, P Sjøgren

14 Citationer (Scopus)

Abstract

Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.

Originalsprog	Engelsk
Tidsskrift	Palliative Medicine
Vol/bind	16
Udgave nummer	2
Sider (fra-til)	107-14
Antal sider	8
ISSN	0269-2163
Status	Udgivet - mar. 2002
Udgivet eksternt	Ja

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

@article{8eff37b00e184604b5b1ca343623b8af,

title = "Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine",

abstract = "Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.",

keywords = "Adult, Aged, Analgesics, Opioid, Delayed-Action Preparations, Female, Humans, Male, Middle Aged, Morphine, Morphine Derivatives, Neoplasms, Pain",

author = "G Andersen and Jensen, {N H} and Christrup, {Lona Louring} and Hansen, {S H} and P Sj{\o}gren",

year = "2002",

month = mar,

language = "English",

volume = "16",

pages = "107--14",

journal = "Palliative Medicine",

issn = "0269-2163",

publisher = "SAGE Publications",

number = "2",

}

TY - JOUR

T1 - Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

AU - Andersen, G

AU - Jensen, N H

AU - Christrup, Lona Louring

AU - Hansen, S H

AU - Sjøgren, P

PY - 2002/3

Y1 - 2002/3

N2 - Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.

AB - Morphine-6-glucuronide (M-6-G) and morphine-3-glucuronide (M-3-G) are the two most important metabolites of morphine. Both are pharmacologically active, however, with different effects. M-6-G has been demonstrated capable of inducing anti-nociception and sedation, and M-3-G may induce behavioural excitation and possibly antagonise anti-nociception. Their impact on pharmacodynamics in patients in long-term treatment with oral morphine remains to be settled.

KW - Adult

KW - Aged

KW - Analgesics, Opioid

KW - Delayed-Action Preparations

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Morphine

KW - Morphine Derivatives

KW - Neoplasms

KW - Pain

M3 - Journal article

C2 - 11969141

SN - 0269-2163

VL - 16

SP - 107

EP - 114

JO - Palliative Medicine

JF - Palliative Medicine

IS - 2

ER -

Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine

Abstract

FN’s Verdensmål

Fingeraftryk

Citationsformater